Donrafylix
Opinion
insulin aspart
MedicineHumanOpinion
Polish is available via eTranslation, the European Commission's machine translation service.
Translate to Polish | Important information about machine translation
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Donrafylix, intended for the treatment of diabetes mellitus.
The applicant for this medicinal product is Kuraci BV.
Donrafylix will be available as 100 units/ml solution for injection. The active substance of Donrafylix is insulin aspart, a fast-acting insulin (ATC code: A10AB05), which has a more rapid onset of action than human soluble insulin. The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Donrafylix is a biosimilar medicinal product. It is highly similar to the reference product NovoRapid (insulin aspart), which was authorised in the EU on 7 September 1999. Data show that Donrafylix has comparable quality, safety and efficacy to NovoRapid .
The full indication is:
Donrafilyx is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.
Biosimilar
This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.